Sugi Predict

Sugi Predict / Compounds / SCHEMBL527235

SCHEMBL527235

SCHEMBL527235

O=C(O)C1CC1c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.58
▸ CYP4A11 Q02928 2/20 0.58
▸ FFAR1 O14842 5/20 0.57
▸ KDM1A O60341 4/20 0.55
▸ MAOB P27338 4/20 0.55
▸ MAOA P21397 3/20 0.55
▸ RAB9A P51151 1/20 0.54
▸ NR4A1 P22736 1/20 0.54
▸ NR4A2 P43354 1/20 0.54
▸ NR4A3 Q92570 1/20 0.54
▸ S1PR5 Q9H228 1/20 0.52
▸ LMNA P02545 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ PTGS1 P23219 1/20 0.51
▸ SLC6A2 P23975 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ SLC6A3 Q01959 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL527236 1.00 CYP4F2 (0.58) CYP4F2CYP4A11FFAR1KDM1AMAOB
SCHEMBL31728652 1.00 CYP4F2 (0.58) CYP4F2CYP4A11FFAR1KDM1AMAOB
SCHEMBL18923955 1.00 CYP4F2 (0.58) CYP4F2CYP4A11FFAR1KDM1AMAOB
SCHEMBL18923951 0.89 KCNH2 (0.58) CYP4F2CYP4A11KDM1AMAOBMAOA
SCHEMBL3749297 0.88 FFAR1 (0.71) CYP4F2CYP4A11FFAR1KDM1AMAOB
SCHEMBL13043524 0.88 FFAR1 (0.71) CYP4F2CYP4A11FFAR1KDM1AMAOB
SCHEMBL19609293 0.87 CYP4F2 (0.57) CYP4F2CYP4A11FFAR1KDM1AMAOB
SCHEMBL15687569 0.87 MAOB (0.52) CYP4F2CYP4A11FFAR1KDM1AMAOB
SCHEMBL1100308 0.87 FFAR1 (0.69) CYP4F2CYP4A11FFAR1MAOA
SCHEMBL2774821 0.86 MAOB (0.54) KDM1AMAOBMAOARAB9ANR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018012-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2024-06-25 — — US disclosed
EP-3495349-B1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS ORYZON GENOMICS SA (ES) 2023-06-28 — — EP disclosed
US-20230130470-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS ALCON INC. (CH) 2023-04-27 — — US disclosed
EP-4074695-A1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS Oryzon Genomics, S.A. (ES) 2022-10-19 — — EP disclosed
US-11312700-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2022-04-26 — — US disclosed
CN-107266345-B (hetero) arylcyclopropylamine compounds as LSD1 inhibitors 奥瑞泽恩基因组学股份有限公司 2021-08-17 — — CN disclosed
US-20210002253-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS ALCON INC. (CH) 2021-01-07 — — US disclosed
US-10858339-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2020-12-08 — — US disclosed
EP-3736265-A1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS Oryzon Genomics, S.A. (ES) 2020-11-11 — — EP disclosed
EP-2768805-B1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS ORYZON GENOMICS SA (ES) 2020-03-25 — — EP disclosed
EP-2598482-A1 ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE Oryzon Genomics, S.A. (ES) 2013-06-05 — — EP disclosed
WO-2013057320-A1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS ORYZON GENOMICS, S.A. (ES) 2013-04-25 — — WO disclosed
WO-2013057322-A1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS ORYZON GENOMICS, S.A. (ES) 2013-04-25 — — WO disclosed
US-8389580-B2 Arylcyclopropylamines and methods of use DUKE UNIVERSITY (US) 2013-03-05 — — US disclosed
US-8389580-B2 Arylcyclopropylamines and methods of use DUKE UNIVERSITY (US) 2013-03-05 — — US disclosed
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 — — US disclosed
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 — — US disclosed
WO-2012013728-A1 ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE ORYZON GENOMICS S.A. (ES) 2012-02-02 — — WO disclosed
US-20100324147-A1 ARYLCYCLOPROPYLAMINES AND METHODS OF USE DUKE UNIVERSITY 2010-12-23 — — US disclosed
US-20100324147-A1 ARYLCYCLOPROPYLAMINES AND METHODS OF USE DUKE UNIVERSITY 2010-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H CYP4F2 3310/4885CYP4A11 2932/4885FFAR1 1470/4885
US-20210002253-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS UACA, HRAS, MYLK CYP4F2 4463/4885CYP4A11 3984/4885FFAR1 2597/4885
US-12018012-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds UACA, HRAS, MYLK CYP4F2 4463/4885CYP4A11 3984/4885FFAR1 2597/4885
US-11312700-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds UACA, HRAS, MYLK CYP4F2 4463/4885CYP4A11 3984/4885FFAR1 2597/4885
US-20100324147-A1 ARYLCYCLOPROPYLAMINES AND METHODS OF USE MAOA, MAOB, PNMT CYP4F2 442/4885CYP4A11 463/4885FFAR1 3779/4885
US-10858339-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds UACA, HRAS, MYLK CYP4F2 4463/4885CYP4A11 3984/4885FFAR1 2597/4885
US-20230130470-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS UACA, HRAS, MYLK CYP4F2 4463/4885CYP4A11 3984/4885FFAR1 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.